MEDI
NEO
saleprice
KONEF
OTC
Ketamine 1 Icon

Ketamine One Subsidiary KGK Science Contracted To Support A Ketamine Clinical Trial In The United States

October 6, 2021

The Trial is to be Conducted in Association with a Clinic Operator in its  Facilities Located in Miami, Florida  

Vancouver, British Columbia, October 6, 2021 / Globe Newswire / – KetamineOne Capital  Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt:  MY0), a company focused on consolidating medical clinics and becoming a North American  leader in mental health treatments, is pleased to announce that its wholly-owned contract research  organization, KGK Science Inc. (“KGK” or the “CRO”), has recently been contracted by a third  party to develop the protocol and Informed Consent Form (“ICF”) to support its Institutional  Review Board application. The engagement of the Company’s CRO by the third party is related  to a ketamine clinical trial that is being planned to be conducted by a clinic operator within its  medical facilities located in Miami, Florida.  

The third party is a provider of digital therapeutics for the psychedelic and mental health sectors.  It will be one of the first companies to collect certain data points and seek to understand how  ketamine can potentially resolve issues in the brain through a process called neuroplasticity. The  required protocol and ICF for the clinical trial in association with the third party are being  developed by KGK in accordance with the guidelines of the International Council for  Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. KGK’s work will  result in a cover letter to support the clinical trial that is being planned to go through an alternate  route to the more traditional Investigational New Drug application.  

The purpose of the study will be to obtain objective data to support the belief that the proper dosing  and administration of intravenous (“IV”) Ketamine treatments can result in neuroplasticity and  sustainable relief from depression, with or without PTSD. Study patients are proposed to each  receive four ketamine infusions. In association with the third party, the clinic operator is proposing  that the ketamine-centered study will measure patients before, during, and after their IV Ketamine  infusions.  

Management Commentary

“We at KGK feel privileged to have been contracted to complete this interesting work. I view the third party as a pioneer in the pursuit of obtaining tangible proof of patient claims about the effectiveness of IV ketamine treatments. If the third party and its partner can record sustainable changes in brain electroencephalograms that correlate strongly to patient outcomes, then they could be on their way to making this protocol a new standard of care. Ultimately, this could lead to bringing more joy into the lives of the millions of people who suffer from a range of insidious psychiatric disorders,” said Najla Guthrie, President & CEO of KGK.  

ABOUT KGK SCIENCE  

Founded in 1997, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on the nutraceutical, cannabis and emerging psychedelic industries. The business has successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies to move products into global markets. KGK’s other existing service lines include expert regulatory support and compliance solutions, participant recruitment, research support services and consulting services. On an approximate basis, the business to date has produced 150 publications, executed over 400 clinical trials across more than 40 indications, amassed 25,000 participants in its database and collected 10 million data points.  

ABOUT KETAMINE ONE

KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on  consolidating medical clinics and becoming a North American leader in mental health treatments.  It is working to provide the critical infrastructure needed to develop and deliver breakthrough  mental health treatments. Currently, Ketamine One has a network of 16 clinics across North  America, with plans to further consolidate the highly fragmented industry. KGK Science Inc. is  the Company’s wholly-owned contract research division, which places it at the forefront of  premium clinical research based on the subsidiary’s 24-year history and extensive experience in  pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective  enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible  mental health therapy.  

On behalf of:  

KETAMINE ONE  

“Adam Deffett”  

Adam Deffett, Interim CEO  

For further information, please contact:  

Nick Kuzyk, Investor Relations  

Tel: 1-844-PHONE-K1 (1-844-746-6351)

Email: IR@ketamine.one  

Web: www.ketamine.one  

Twitter: @KetamineOne  

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements  regarding the Company’s business, assets or investments, as well other statements that are not  historical facts. Readers are cautioned not to place undue reliance on forward-looking statements,  as there can be no assurance that the plans, intentions or expectations upon which they are based  will occur. By their nature, forward-looking statements involve numerous assumptions, known  and unknown risks and uncertainties, both general and specific, that contribute to the possibility  that the predictions, forecasts, projections and other forward-looking statements will not occur,  which may cause actual performance and results in future periods to differ materially from any  estimates or projections of future performance or results expressed or implied by such forward

looking statements. These assumptions, risks and uncertainties include, among other things, the  state of the economy in general and capital markets in particular, investor interest in the business  and prospects of the Company.  

The forward-looking statements contained in this news release are made as of the date of this news  release. Except as required by law, the Company disclaims any intention and assumes no  obligation to update or revise any forward-looking statements, whether as a result of new  information, future events or otherwise, except as required by applicable securities law.  Additionally, the Company undertakes no obligation to comment on the expectations of, or  statements made, by third parties in respect of the matters discussed above.